Tweet
Copyright 2003 Health & Medicine Week via NewsRx.com and NewsRx.net
Health & Medicine Week
October 27, 2003
SECTION: EXPANDED REPORTING; Pg. 129
LENGTH: 444 words
HEADLINE: CARDIOMYOPATHY: Echocardiography shows sustained improvement in PG,
septal walls
BODY:
Echocardiography shows sustained improvement in PG, septal, and left
ventricular posterior wall thicknesses.
According to a study from Japan, "Percutaneous transluminal septal myocardial
ablation (PTSMA) is a new therapeutic option for patients with hypertrophic
obstructive cardiomyopathy (HOCM).
"In the present study, the acute and follow-up results of PTSMA were
evaluated. From August 1997 to March 2003, 27 medically refractory patients (New
York Heart Association (NYHA) functional class 2.9plusmn0.6) with HOCM underwent
PTSMA," wrote E. Tsuchikane and colleagues, Osaka Medical Center, Cancer &
Cardiovascular Diseases, Department of Cardiology.
"The target septal branch was determined by probationary ballooning in three
and by myocardial contrast echocardiography in 24 patients. The mean resting
left ventricular outflow tract pressure gradient (PG) was reduced from
70plusmn44 to 24plusmn22 mmHg (p<.0001); the peak concentration of creatine
kinase was 1,545plusmn686 IU/L," the researchers wrote.
"Although transient trifascicular block was observed in 14 patients,
permanent pacemaker implantation was not required. There were no major adverse
cardiac events during the hospital stay; the mean clinical follow-up was
2.2plusmn1.7 years. Repeated PTSMA was needed in one patient; however,
symptomatic improvement had been well preserved in all patients (NYHA class
1.2plusmn0.4)," the researchers stated.
The researchers concluded: "Follow-up echocardiographic examination showed
sustained improvement in PG, septal, and left ventricular posterior wall
thicknesses, and the grade of systolic anterior movement and regurgitation of
the mitral valve. PTSMA is a safe and effective therapeutic option for medically
refractory patients with HOCM."
Tsuchikane and colleagues published their study in Circulation Journal
(Percutaneous transluminal septal myocardial ablation for hypertrophic
obstructive cardiomyopathy - Initial and follow-up results in the first 27
patients. Circ J, 2003;67(9):763-767).
For more information, contact E. Tsuchikane, Osaka Medical Center, Cancer &
Cardiovascular Diseases, Department of Cardiology, Higashinari Ku, 1-3-3
Nakamichi, Osaka 5378511, Japan.
Publisher contact information for the Circulation Journal is: Blackwell
Publishing Asia, 54 University St., PO Box 378, Carlton, Victoria 3053,
Australia.
The information in this article comes under the major subject area of Medical
Devices.
This article was prepared by Health & Medicine Week editors from staff and
other reports.
http://www.NewsRx.net
LOAD-DATE: October 24, 2003
Health & Medicine Week
October 27, 2003
SECTION: EXPANDED REPORTING; Pg. 129
LENGTH: 444 words
HEADLINE: CARDIOMYOPATHY: Echocardiography shows sustained improvement in PG,
septal walls
BODY:
Echocardiography shows sustained improvement in PG, septal, and left
ventricular posterior wall thicknesses.
According to a study from Japan, "Percutaneous transluminal septal myocardial
ablation (PTSMA) is a new therapeutic option for patients with hypertrophic
obstructive cardiomyopathy (HOCM).
"In the present study, the acute and follow-up results of PTSMA were
evaluated. From August 1997 to March 2003, 27 medically refractory patients (New
York Heart Association (NYHA) functional class 2.9plusmn0.6) with HOCM underwent
PTSMA," wrote E. Tsuchikane and colleagues, Osaka Medical Center, Cancer &
Cardiovascular Diseases, Department of Cardiology.
"The target septal branch was determined by probationary ballooning in three
and by myocardial contrast echocardiography in 24 patients. The mean resting
left ventricular outflow tract pressure gradient (PG) was reduced from
70plusmn44 to 24plusmn22 mmHg (p<.0001); the peak concentration of creatine
kinase was 1,545plusmn686 IU/L," the researchers wrote.
"Although transient trifascicular block was observed in 14 patients,
permanent pacemaker implantation was not required. There were no major adverse
cardiac events during the hospital stay; the mean clinical follow-up was
2.2plusmn1.7 years. Repeated PTSMA was needed in one patient; however,
symptomatic improvement had been well preserved in all patients (NYHA class
1.2plusmn0.4)," the researchers stated.
The researchers concluded: "Follow-up echocardiographic examination showed
sustained improvement in PG, septal, and left ventricular posterior wall
thicknesses, and the grade of systolic anterior movement and regurgitation of
the mitral valve. PTSMA is a safe and effective therapeutic option for medically
refractory patients with HOCM."
Tsuchikane and colleagues published their study in Circulation Journal
(Percutaneous transluminal septal myocardial ablation for hypertrophic
obstructive cardiomyopathy - Initial and follow-up results in the first 27
patients. Circ J, 2003;67(9):763-767).
For more information, contact E. Tsuchikane, Osaka Medical Center, Cancer &
Cardiovascular Diseases, Department of Cardiology, Higashinari Ku, 1-3-3
Nakamichi, Osaka 5378511, Japan.
Publisher contact information for the Circulation Journal is: Blackwell
Publishing Asia, 54 University St., PO Box 378, Carlton, Victoria 3053,
Australia.
The information in this article comes under the major subject area of Medical
Devices.
This article was prepared by Health & Medicine Week editors from staff and
other reports.
http://www.NewsRx.net
LOAD-DATE: October 24, 2003